incyte biosciences distribution b.v. - pemigatinib - cholangiocarcinoma - Αντινεοπλασματικοί παράγοντες - pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Ευρωπαϊκή Ένωση -
Ελληνικά -
EMA (European Medicines Agency)